ECE: Phase I Clinical Trial Preliminary Results

In a 2 month, double-blinded study of recognized fibromyalgia patients, ECE was administered as an additional therapy to the patients’ current standard of Doctor care. The results established the general safety of ECE. ECE cut the time it took the participants to fall asleep by 47 minutes; it augmented total nighttime sleep by 1.6 hours; it improved depth of sleep by 80%; it boosted their energy levels by70%; it gave them 2 1/4 more good days per week; it helped decrease their pain by 30%; and their general condition improved by 40%. Interestingly, these improvements were achieved at all doses. Patients given the placebo had no improvement during the study.